Clinical effect of lenalidomide combined with low-dose dexamethasone in the treatment of multiple myeloma
Objective To analyze the clinical effect of lenalidomide combined with low-dose dexamethasone in the treatment of multiple myeloma.Methods A total of 50 patients with multiple myeloma admitted in our hospital from January 2018 to December 2022 were selected as the research objects,according to the dose difference of dexamethasone,the patients were divided into group A(lenalidomide combined with high-dose dexamethasone)and group B(lenalidomide combined with low-dose dexamethasone),with 25 cases in each group.The therapeutic effects of the two groups were compared.Results There was no significant difference in the total effective rate of treatment between the two groups(P>0.05).After treatment,the hemoglobin(HGB),molecular fragment of osteocalcin N terminal(N-MID),bone growth protein(BGP)levels and bone mineral density(BMD)increased,the levels of erythrocyte sedimentation rate(ESR),β2-microglobulin(β2-MG),creatinine(Cre),interleukin-1β(IL-1β),interleukin-8(IL-8),vascular endothelial growth factor(VEGF),epidermal growth factor(EGF)and β-C-terminal telopeptide of type-Ⅰ collagen(β-CTX)decreased in both groups,and those in the group B were better than the group A(P<0.05).The total incidence of adverse reactions during treatment in the group B was lower than that in the group A(P<0.05).Conclusion Lenalidomide combined with low-dose dexamethasone in the treatment of multiple myeloma can effectively improve liver and kidney function and regulate bone metabolism,without increasing adverse reactions,so as to achieve ideal curative effect.
NETL
NSTL
万方数据
